Understanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care data
Preprint
Abstract
Background: Statins are commonly prescribed to lower LDL cholesterol. Clinical guidelines recommend 30-50% reduction within 3 months, yet many patients do not achieve this. We investigated the impact of patient characteristics and genetics on LDL-c reduction, treatment adherence, and adverse clinical outcomes. Methods: We analysed 76,000 UK Biobank participants prescribed atorvastatin or simvastatin in primary care: 41,000 had LDL-c measurements before statin initiation (median=16 days prior, IQR=28) and within a year of starting treatment (median=89 days, IQR=125). Adherence was defined as the “proportion of days covered” (PDC). We estimated associations between PDC within one year of statin initiation, genetic factors, post-treatment LDL reduction, and clinical adverse outcomes. For 13,000 patients with ≥3 LDL-c measures, we used inverse probability weighting methods to estimate the effect of sustained adherence intervention on LDL-c reduction longitudinally. Results: Predictors of LDL-c reduction following statin initiation included the time until the 1 st measurement, PDC, and the pharmacogenetic variant SLCO1B1 *5. LDL-c reduction was greater in those with high adherence versus lower adherence (38% reduction when PDC>95% [high] vs. 15% when PDCtop 20% -1.94, 95%CI -2.69 to -1.19), whilst genetic liability to cardiovascular diseases increased PDC (Coef top 20% 1.30, 95%CI 0.55 to 2.05). High PDC was associated with increased risk of incident iron deficiency anaemia (HR 1.30, 95%CI 1.09-1.54) and cataract (HR 1.20, 95%CI 1.07-1.34), and decreased risk of incident coronary heart disease (HR 0.78, 95%CI 0.73-0.84). Conclusion: We identify substantial variability in the time to first on-treatment LDL measurements and also in adherence to statin medication, highlighting a gap between NHS guidelines, LDL monitoring and statin adherence. We show its subsequent impact on long term health, demonstrating the potential effect of targeted interventions to improve adherence. We identify important predictors of reduced statin effectiveness, including pharmacogenetic variants, polygenic scores, but most of all, adherence. Tailored statin therapy strategies with patient education on statin indication and adherence could optimise treatment efficacy, safety, and long-term clinical outcomes.Keywords
All Related Versions
- Published version: BMC Medicine, 23 (1), 1.
This publication has 43 references indexed in Scilit:
- Genetic predisposition and antipsychotic treatment effect on metabolic syndrome in schizophrenia: a ten-year follow-up study using the Estonian BiobankThe Lancet Regional Health - Europe, 2024
- 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease RiskJACC, 2022
- The Global Burden of Cardiovascular Diseases and RisksJACC, 2020
- A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or HypertriglyceridemiaJAMA Cardiology, 2020
- Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular DiseaseJAMA Cardiology, 2019
- Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary SyndromeJACC, 2015
- Register-based predictors of adherence among new statin users in FinlandJournal of Clinical Lipidology, 2014
- How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy?Current Atherosclerosis Reports, 2012
- Medication adherence: A call for actionAmerican Heart Journal, 2011
- Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary SyndromesJAMA, 2004